

IFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paper Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/805,788	
	Filing Date	Mar 22, 2004	
	First Named Inventor	Quay, Steven C.	
	Art Unit	1614	
	Examiner Name		
Total Number of Pages in This Submission	189	Attorney Docket Number	03-04US


ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance communication to (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1) Form 1449A (3 pgs) 2) International Search Report (5 pgs) 3) Foreign References (181 pgs)
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Nestec Pharmaceutical Company Inc.		
Signature			
Printed name	Peter J. Knudsen		
Date	August 19, 2005	Reg. No.	40682

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name	Jeffrey L. Granger	Date	August 19, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

In you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Quay et al.

Group Art Unit: 1614

Serial No.: 10/805,788

Attorney Docket No.: 03-04US

Filed: 3/22/2004

Title: NASAL CALCITONIN
FORMULATIONS CONTAINING
CHLOROBUTANOL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Information Disclosure Statement is submitted:

- ☒ under 37 CFR 1.97(b), or
(Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)
- ☐ under 37 CFR 1.97(c) together with either a:
☐ Statement under 37 CFR 1.97(e), or
☐ a \$180.00 fee under 37 CFR 1.17(p), or
(After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with a:
☐ Statement under 37 CFR 1.97(e), and
☐ a \$180.00 fee set forth in 37 CFR 1.17(p).
(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

☒ Applicant(s) submit herewith Form PTO 1449-Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references is that this is the closest art of which Applicant is aware. Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.



Respectfully submitted,

I hereby certify that this Correspondence is being deposited with the United States Postal service with sufficient postage for first class mail in an envelope address to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or the correspondence is being facsimile transmitted to the USPTO, on the date indicated below.

Date of Deposit: August 19, 2005

Typed Name: Jeffrey L. Granger

Signature: _____




Peter J. Knudsen

Attorney/Agent for Applicant(s)

Reg. No. 40682

Date: August 19, 2005

Telephone No.: 425-908-3643



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Patent Work Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/805,788
Filing Date	3/22/2004
First Named Inventor	Quay et al.
Art Unit	1614
Examiner Name	
Attorney Docket Number	03-04US

Sheet 1 of 3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-4,670,419	Issued 06-02-1987	Takeda Chemical Industries, Ltd.	
		US-4,690,952	Issued 09-01-1987	Yamanouchi Pharmaceutical Co., Inc.	
		US-4,788,221	Issued 11-29-1988	Yamanouchi Pharmaceutical Co., Ltd.	
		US-4,985,242	Issued 01-15-1991	Teijin Limited	
		US-4,988,512	Issued 09-18-1989	Sandoz Ltd.	
		US-5,026,825	Issued 06-25-1991	Rhone-Poulenc Rorer Pharmaceuticals, Inc.	
		US-5,059,587	Issued 10-22-1991	Toyo Jozo Company, Ltd.	
		US-5,091,365	Issued 02-25-1992	Hoechst Aktiengesellschaft	
		US-5,112,804	Issued 05-12-1992	Temple University of the Commonwealth System of Higher Education	
		US-5,124,315	Issued 06-23-1992	Phideatech S.R.L.	
		US-5,153,308	Issued 10-06-1992	Teijin Limited	
		US-5,179,079	Issued 01-12-1993	Novo Nordisk A/S	
		US-5,183,802	Issued 02-02-1993	ISF Societa per Azioni	
		US-5,200,393	Issued 04-06-1993	The Liposome Company, Inc.	
		US-5,204,108	Issued 04-20-1993	Danbiosyst UK Ltd.	
		US-5,211,950	Issued 05-18-1993	Teijin Limited	
		US-5,215,739	Issued 06-01-1993	Toko Yakuhin Kogyo Kabushiki Kaisha	
		US-5,281,580	Issued 01-25-1994	Toyo Jozo Company, Ltd.	
		US-5,321,008	Issued 06-14-1994	Amylin Pharmaceuticals, Inc.	
		US-5,428,006	Issued 06-27-1995	Bechgaard International Research and Development A/S	

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		FR 2,205,308	05-31-1974	Farbwerke Hoechst AG		
		EP 0 111 841 A1	06-27-1984	Syntex (U.S.A.) Inc.		
		EP 0 115 627 A1	08-15-1984	Armour Pharmaceutical Company		
		EP 0 183 527 B1	06-04-1986	Yamanouchi Pharmaceutical Co. Ltd.		
		EP 0 193 372 A2	09-03-1986	Teijin Limited		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/805,788
Filing Date	3/22/2004
First Named Inventor	Quay et al.
Art Unit	1614
Examiner Name	
Attorney Docket Number	03-04US

Sheet

2

of

3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-5,428,706	Issued 6-27-1995	Coflexip	
		US-5,482,931	Issued 01-09-1996	Ferring AB	
		US-5,503,827	Issued 04-02-1996	Boehringer Mannheim GmbH	
		US-5,508,260	Issued 04-16-1996	Amylin Pharmaceuticals, Inc.	
		US-5,514,365	Issued 05-07-1996	Schiapparelli Salute S.P.A.	
		US-5,527,771	Issued 06-18-1996	Amylin Pharmaceuticals, Inc.	
		US-5,554,378	Issued 09-10-1996	Takeda Chemical Industries, Ltd.	
		US-5,565,423	Issued 10-15-1996	Hoechst Aktiengesellschaft	
		US-5,574,006	Issued 11-12-1996	Dott Research Laboratory	
		US-5,576,016	Issued 11-19-1996	Pharmos Corporation	
		US-5,578,324	Issued 11-26-1996	Teijin Limited	
		US-5,603,943	Issued 02-18-1997	Dott Research Laboratory	
		US-5,654,000	Issued 08-05-1997	Poli Industria Chimica S.p.A.	
		US-5,681,811	Issued 10-28-1997	Protein Delivery, Inc.	
		US-5,693,608	Issued 12-02-1997	Bechgaard International Research and Development A/S	
		US-5,719,122	Issued 02-17-1998	SmithKline Beecham Farmaceutici S.p.A.	
		US-5,725,852	Issued 03-10-1998	Takeda Chemical Industries, Ltd.	
		US-5,725,871	Issued 03-10-1998	Danbiosyst UK Limited	
		US-5,733,569	Issued 03-31-1998	Novartis Corporation	

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		GB 2 177 914 A	02-04-1987	Chugai Seiyaku Kabushiki Kaisha		
		EP 0 358 234 A2	03-14-1990	Rorer International (Overseas) Inc.		
		EP 0 371 010 A1	05-30-1990	Yamanouchi Pharmaceutical Co. Ltd.		
		EP 0 418 697 A1	03-27-1991	Esseit s.a.s. Laboratorio Chimico Farmaco Biologico Di A. Ievoli & C.		
		EP 0 471 618 A1	08-12-1991	Toyo Jozo Co., Ltd.		
		EP 0 489 217 A1	06-10-1992	DR. A. Tosi Farmaceutici S.R.L.		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/805,788
Filing Date	3/22/2004
First Named Inventor	Quay et al.
Art Unit	1614
Examiner Name	
Attorney Docket Number	03-04US

Sheet

3

of

3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-5,759,565	Issued 06-02-1998	Novartis Corporation	
		US-5,859,048	Issued 01-12-1999	Teikoku Hormone MFG. Co., Ltd.	
		US-5,948,749	Issued 09-07-1999	Fuji Yakuhin Company, Limited	
		US-6,078,338	Issued 07-11-2000	Therapicon S.R.L.	
		US-6,149,893	Issued 11-21-2000	Alfa Wasserman S.p.A.	
		US-6,161,731	Issued 12-19-2000	Novartis AG	
		US-6,174,857 B1	Issued 01-16-2001	Novartis Corporation	
		US-6,221,367 B1	Issued 04-24-2001	Emisphere Technologies, Inc.	
		US-20020010428 A1	01-24-2002	Vedrine, Lionel; et al.	
		US-20020012688 A1	01-31-2002	Dohi, Masahiko; et al.	
		US-20020015737 A1	02-07-2002	MacroMed, Incorporated	
		US-20020031558 A1	03-14-2002	Yoo, Seo Hong	
		US-20020037836 A1	03-28-2002	Henriksen, Dennis Bang	
		US-20020068092 A1	06-06-2002	Bosch, H. William; et al.	
		US-20020076441 A1	06-20-2002	MacroMed, Inc.	
		US-20020107265 A1	08-08-2002	Chen, Feng-Jing; et al.	
		US-20020110525 A1	08-15-2002	Adjei, Akwete L.; et al.	
		US-20020110527 A1	08-15-2002	Zhu, Yaping; et al.	
		US-20020110528 A1	08-15-2002	Zhu, Yaping; et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		WO 99/16427 (Int. App. No. PCT/US98/20548)	04-08-1999	Emisphere Technologies, Inc.		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.